Cambridge University signs partnership to address innovation challenges
The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.
The collaboration is supported by a £4 million ($5.6 million) grant awarded by the Denmark-based Novo Nordisk Foundation to professor Timo Minssen, the director of the University of Copenhagen’s centre for advanced studies in biomedical innovation law (CeBIL).
Other key partners include Harvard Law School, Harvard Medical School, and the University of Michigan Law School.
The partnership will analyse the challenges facing pharmaceutical innovation and public health from a cross-disciplinary perspective.
Kathy Liddell, director of the University of Cambridge’s centre for law, medicine and life sciences (LML), said: “The research undertaken by CeBIL will make a pioneering contribution to the field of biomedical innovation. We are delighted to be part of the enterprise.”
Jeffrey Skopek, deputy director of the LML, added that rapid advances in medicine and the life sciences, alongside changing societal attitudes towards health and medical care, “pose deeply challenging questions of law, ethics, and policy”.
The collaboration was announced on Wednesday, January 24.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.
